4//SEC Filing
SCHAFFER DAVID 4
Accession 0001567619-21-017624
CIK 0001650648other
Filed
Sep 28, 8:00 PM ET
Accepted
Sep 29, 4:05 PM ET
Size
12.5 KB
Accession
0001567619-21-017624
Insider Transaction Report
Form 4
SCHAFFER DAVID
Director10% Owner
Transactions
- Sale
Common Stock
2021-09-28$30.52/sh−13,812$421,493→ 966,856 total - Sale
Common Stock
2021-09-27$32.59/sh−13,075$426,076→ 986,925 total - Sale
Common Stock
2021-09-27$34.19/sh−100$3,419→ 980,668 total - Sale
Common Stock
2021-09-27$33.51/sh−6,157$206,330→ 980,768 total - Sale
Common Stock
2021-09-28$32.00/sh−100$3,200→ 966,756 total
Footnotes (5)
- [F1]Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
- [F2]The transaction was executed in multiple trades in prices ranging from $32.09 to $33.09, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F3]Since the date of the reporting person's last ownership report, he transferred 1,000,000 shares of FDMT common stock to his ex-spouse pursuant to a domestic relations order. The reporting person no longer reports as beneficially owned any securities owned by his ex-spouse.
- [F4]The transaction was executed in multiple trades in prices ranging from $33.10 to $34.01, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F5]The transaction was executed in multiple trades in prices ranging from $30.28 to $31.19, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Documents
Issuer
4D Molecular Therapeutics Inc.
CIK 0001650648
Entity typeother
Related Parties
1- filerCIK 0001692929
Filing Metadata
- Form type
- 4
- Filed
- Sep 28, 8:00 PM ET
- Accepted
- Sep 29, 4:05 PM ET
- Size
- 12.5 KB